COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804


Print ISSN:-2581-5024

Online ISSN:-2581-5016

CODEN : IIJOBU

Current Issue

Year 2020

Volume: 6 , Issue: 1

Article Access statistics

Viewed: 567

Emailed: 0

PDF Downloaded: 224

IP International Journal of Ocular Oncology and Oculoplasty


Chemotherapy for Retinoblastoma


Full Text PDF Share on Facebook Share on Twitter


Author Details : Rajarathna Thangavel, Hakan Demirci

Volume : 2, Issue : 4, Year : 2016

Article Page : 222-226


Suggest article by email

Abstract

Retinoblastoma is the most common primary malignant intraocular tumor of childhood. It has a mortality close to 60% in the developing world. With early diagnosis and treatment, survival rates could be high as 95%. Management of Retinoblastoma has undergone a paradigm change in the past two decades with globe salvage becoming the goal of treatment. Safety and efficacy of chemotherapeutic agents combined with their targeted delivery has increased the success rates of tumor control. This article reviews the treatment strategies using different routes of drug delivery to contain ocular and extraocular retinoblastoma, the risks and benefits and future of chemotherapy.

Keywords: Retinoblastoma, Chemotherapy, Intra-arterial melphalan, IAC, Intravitreal melphalan, Periocular cisplatin, VEC regimen

 

How to cite : Thangavel R, Demirci H, Chemotherapy for Retinoblastoma. IP Int J Ocul Oncol Oculoplasty 2016;2(4):222-226

Copyright © 2016 by author(s) and IP Int J Ocul Oncol Oculoplasty. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (creativecommons.org)